Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-5172/MK-8742 in treatment-naive chronic HCV/HIV coinfected adults
2014-000342-30Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of grazoprevir and verubecestat in chronic hepatitis C (CHC), sponsored by Merck & Co. Primary endpoints: SVR12 and SVR24. Started Apr 2014; status: completed.
02
Drugs
grazoprevirverubecestat
03
Conditions
chronic hepatitis C (CHC)
Beyond the preview
Go deeper on 2014-000342-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000342-30.